Goldman's O'Neill Retires, Ahmadinejad Shoe Attack

Feb. 6 (Bloomberg) -- Bloomberg's Sara Eisen reports on today's "Top Headlines." She speaks on Bloomberg Television's "Bloomberg Surveillance."

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
03:19 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn